Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Optimized Cyclophosphamide (CY) Dosing in Combination with Fludarabine, TBI and ATG As Conditioning for Unrelated Donor Bone Marrow Transplantation (BMT) in Severe Aplastic Anemia (SAA): A Phase I/II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)

Paolo Anderlini, MD, Juan Wu, MS, H. Joachim Deeg, MD, Iris Gersten, MS, Marian Ewell, ScD, Jakub Tolar, MD PhD, Joseph H. Antin, MD, Sally Arai, MD, Mitchell E. Horwitz, MD, John M. McCarty, MD, Ryotaro Nakamura, MD, Michael A. Pulsipher, MD, Roberta H. Adams, MD, Eric Leifer, PhD, Shelly L Carter, ScD, Nancy L DiFronzo, PhD, Mary M. Horowitz, MD MS, Dennis L. Confer, MD, Mary Eapen, MBBS, MS

Blood (2014) 124 (21): 541.

https://doi.org/10.1182/blood.V124.21.541.541

Published: 2014

Journal Articles

Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802

Javier Bolaños-Meade, Brent R. Logan, Amin M. Alousi, Joseph H. Antin, Kate Barowski, Shelly L. Carter, Steven C. Goldstein, Elizabeth O. Hexner, Mary M. Horowitz, Stephanie J. Lee, John E. Levine, Margaret L. MacMillan, Paul J. Martin, Adam M. Mendizabal, Ryotaro Nakamura, Marcelo C. Pasquini, Daniel J. Weisdorf, Peter Westervelt, Vincent T. Ho

Blood (2014) 124 (22): 3221–3227.

https://doi.org/10.1182/blood-2014-06-577023

Published: 2014

Journal Articles

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT

Corey Cutler, Brent Logan, Ryotaro Nakamura, Laura Johnston, Sung Choi, David Porter, William J. Hogan, Marcelo Pasquini, Margaret L. MacMillan, Jack W. Hsu, Edmund K. Waller, Stephan Grupp, Philip McCarthy, Juan Wu, Zhen-Huan Hu, Shelly L. Carter, Mary M. Horowitz, Joseph H. Antin

Blood (2014) 124 (8): 1372–1377.

https://doi.org/10.1182/blood-2014-04-567164

Published: 2014

Journal Articles

A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502

Blood (2012) 120 (21): 230.

https://doi.org/10.1182/blood.V120.21.230.230

Published: 2012

Journal Articles

Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402

Corey Cutler, MD, MPH, FRCPC, Brent R. Logan, PhD, Ryotaro Nakamura, MD, Laura Johnston, MD, Sung W. Choi, M.D., David L Porter, MD, William J Hogan, MBBCh, Marcelo C Pasquini, MD, MS, Margaret L. MacMillan, MD, John R. Wingard, MD, Edmund K. Waller, MD, PhD, Stephan A. Grupp, MD, PhD, Philip L. McCarthy, MD, Juan Wu, MS, Zhenhuan Hu, MPH, Shelly L Carter, ScD, Mary M. Horowitz, MD, MS, Joseph H. Antin, MD

Blood (2012) 120 (21): 739.

https://doi.org/10.1182/blood.V120.21.739.739

Published: 2012

Journal Articles

No Survival Advantage After Double Umbilical Cord Blood (UCB) Compared to Single UCB Transplant in Children with Hematological Malignancy: Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501) Randomized Trial

John E. Wagner, MD, Mary Eapen, MBBS, Shelly L Carter, ScD, Paul R. Haut, MD, Edward Peres, MD, Kirk R. Schultz, MD, Jason Thompson, Donna A. Wall, MD, Joanne Kurtzberg, MD

Blood (2012) 120 (21): 359.

https://doi.org/10.1182/blood.V120.21.359.359

Published: 2012

Journal Articles

Increased Incidence of Chronic Graft-Versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial

Blood (2011) 118 (21): 1.

https://doi.org/10.1182/blood.V118.21.1.1

Published: 2011

Journal Articles

Immunoglobulin Free Light Chain (FLC) and Heavy Chain/Light Chain (HLC) Assays – Comparison with Electrophoretic Responses in Multiple Myeloma (MM)

Parameswaran Hari, MBBS, MD, MRCP, Marcelo C Pasquini, MD, MS, Brent R. Logan, PhD, Edward A. Stadtmauer, MD, Amrita Krishnan, MD, Alan Howard, PhD, Sairah Alvi, PhD, Stephen Harding, Shelly L Carter, ScD, Vincent Rajkumar, MD, Edwin P Alyea, III, MD, Muzaffar Qazilbash, MD, Ginna G. Laport, MD, David G. Maloney, MD, PhD, Sergio Giralt, MD, David H. Vesole, MD, PhD

Blood (2011) 118 (21): 2877.

https://doi.org/10.1182/blood.V118.21.2877.2877

Published: 2011

Journal Articles

Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels

Jakub Tolar, MD, PhD, H. Joachim Deeg, M.D., Sally Arai, MD, Mitchell Horwitz, MD, Joseph H. Antin, MD, John M. McCarty, MD, Roberta H. Adams, MD, Mary Eapen, MBBS, Marian Ewell, ScD, Eric Leifer, PhD, Iris Gersten, MS, Shelly L Carter, ScD, Mary M. Horowitz, MD, Dennis L Confer, MD, Ryotaro Nakamura, MD, Michael Pulsipher, MD, Nancy L DiFronzo, PhD, Paolo Anderlini, MD

Blood (2011) 118 (21): 3009.

https://doi.org/10.1182/blood.V118.21.3009.3009

Published: 2011

Journal Articles

Randomized Phase III Trial of 131 iodine-Tositumomab (Bexxar)/Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) Vs. Rituximab/BEAM and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL): No Difference in Progression-Free (PFS) or Overall Survival (OS)

Julie M Vose, MD, Shelly L Carter, ScD, Linda J Burns, MD, Ernesto Ayala, MD, Oliver W. Press, MD, PhD, Craig H. Moskowitz, MD, Edward A. Stadtmauer, MD, Shin Mineishi, MD, Richard F. Ambinder, Timothy S. Fenske, MD, Mary M. Horowitz, MD, Marcie Tomblyn, MD, MS

Blood (2011) 118 (21): 661.

https://doi.org/10.1182/blood.V118.21.661.661

Published: 2011

Journal Articles

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts

Claudio G. Brunstein, Ephraim J. Fuchs, Shelly L. Carter, Chatchada Karanes, Luciano J. Costa, Juan Wu, Steven M. Devine, John R. Wingard, Omar S. Aljitawi, Corey S. Cutler, Madan H. Jagasia, Karen K. Ballen, Mary Eapen, Paul V. O'Donnell, on behalf of the Blood and Marrow Transplant Clinical Trials Network

Blood (2011) 118 (2): 282–288.

https://doi.org/10.1182/blood-2011-03-344853

Published: 2011

Journal Articles

Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation

John R. Wingard, Shelly L. Carter, Thomas J. Walsh, Joanne Kurtzberg, Trudy N. Small, Lindsey R. Baden, Iris D. Gersten, Adam M. Mendizabal, Helen L. Leather, Dennis L. Confer, Richard T. Maziarz, Edward A. Stadtmauer, Javier Bolaños-Meade, Janice Brown, John F. DiPersio, Michael Boeckh, Kieren A. Marr, for The Blood and Marrow Transplant Clinical Trials Network

Blood (2010) 116 (24): 5111–5118.

https://doi.org/10.1182/blood-2010-02-268151

Published: 2010

Includes: Supplemental data

Journal Articles

Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies

Joanne Kurtzberg, Vinod K. Prasad, Shelly L. Carter, John E. Wagner, Lee Ann Baxter-Lowe, Donna Wall, Neena Kapoor, Eva C. Guinan, Stephen A. Feig, Elizabeth L. Wagner, Nancy A. Kernan

Blood (2008) 112 (10): 4318–4327.

https://doi.org/10.1182/blood-2007-06-098020

Published: 2008

Journal Articles

Results of a Randomized, Double-Blind Trial of Fluconazole (FLU) vs. Voriconazole (VORI) for the Prevention of Invasive Fungal Infections (IFI) in 600 Allogeneic Blood and Marrow Transplant (BMT) Patients.

John R. Wingard, Shelly L. Carter, Thomas J. Walsh, Joanne Kurtzberg, Trudy N. Small, Iris D. Gersten, Adam M. Mendizabal, Helen Leather, Dennis L. Confer, Lindsey R. Baden, Richard T. Maziarz, Edward A. Stadtmauer, Javier Bolanos-Meade, Janice Brown, John F. DiPersio, Michael Boeckh, Kieren A. Marr

Blood (2007) 110 (11): 163.

https://doi.org/10.1182/blood.V110.11.163.163

Published: 2007

Journal Articles

Effect of Graft Engineering and Post-Transplantation Immunosuppression Regimen on Immunophenotypic Recovery in Recipients of Unrelated Donor Bone Marrow (T-Cell Depletion Trial) in a Multicenter Randomized Phase II-III Trial.

Lawrence S. Lamb, PhD, John E. Wagner, MD, Nancy A. Kernan, MD, Trudy N. Small, MD, Shelly L. Carter, PhD, John S. Thompson, MD, Gretchen A. Cloud, PhD, Sreelatha Meleth, PhD, Anand Kumar, MD, Carolyn A. Keever-Taylor, PhD

Blood (2007) 110 (11): 1067.

https://doi.org/10.1182/blood.V110.11.1067.1067

Published: 2007

Journal Articles

Post-Thaw Colony Forming Unit (CFU) Counts and Yield Are the Most Important Predictors of Engraftment and Survival Following Unrelated Donor Cord Blood Transplantation (CBT): A COBLT Study Report.

Donna A. Wall, MD, Elizabeth L. Wagner, M.P.H., Shelly L. Carter, Sc.D., Adam M. Mendizabal, MS, Mitchell S. Cairo, MD, Nancy A. Kernan, MD, Mary Laughlin, MD, Joanne Kurtzberg, MD

Blood (2005) 106 (11): 2046.

https://doi.org/10.1182/blood.V106.11.2046.2046

Published: 2005

Journal Articles

Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation

Steven Z. Pavletic, Shelly L. Carter, Nancy A. Kernan, Jean Henslee-Downey, Adam M. Mendizabal, Esperanza Papadopoulos, Roger Gingrich, James Casper, Saul Yanovich, Daniel Weisdorf, for the members of the National Heart, Lung, and Blood Institute Unrelated Donor Marrow Transplantation Trial

Blood (2005) 106 (9): 3308–3313.

https://doi.org/10.1182/blood-2005-04-1614

Published: 2005

NARROW

Optimized Cyclophosphamide (CY) Dosing in Combination with Fludarabine, TBI and ATG As Conditioning for Unrelated Donor Bone Marrow Transplantation (BMT) in Severe Aplastic Anemia (SAA): A Phase I/II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)

Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT

A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502

Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402

No Survival Advantage After Double Umbilical Cord Blood (UCB) Compared to Single UCB Transplant in Children with Hematological Malignancy: Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501) Randomized Trial

Immunoglobulin Free Light Chain (FLC) and Heavy Chain/Light Chain (HLC) Assays – Comparison with Electrophoretic Responses in Multiple Myeloma (MM)

Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels

Randomized Phase III Trial of 131 iodine-Tositumomab (Bexxar)/Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) Vs. Rituximab/BEAM and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL): No Difference in Progression-Free (PFS) or Overall Survival (OS)

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts

Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation

Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies

Results of a Randomized, Double-Blind Trial of Fluconazole (FLU) vs. Voriconazole (VORI) for the Prevention of Invasive Fungal Infections (IFI) in 600 Allogeneic Blood and Marrow Transplant (BMT) Patients.

Effect of Graft Engineering and Post-Transplantation Immunosuppression Regimen on Immunophenotypic Recovery in Recipients of Unrelated Donor Bone Marrow (T-Cell Depletion Trial) in a Multicenter Randomized Phase II-III Trial.

Post-Thaw Colony Forming Unit (CFU) Counts and Yield Are the Most Important Predictors of Engraftment and Survival Following Unrelated Donor Cord Blood Transplantation (CBT): A COBLT Study Report.

Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only